Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yu Chen Sh Yang"'
Autor:
Hung-Yun Lin, Shu-Leei Tey, Yih Ho, Yung-Tang Chin, Kuan Wang, Jacqueline Whang-Peng, Ya-Jung Shih, Yi-Ru Chen, Yung-Ning Yang, Yu-Cheng Chen, Yi-Chang Liu, Heng-Yuan Tang, Yu-Chen SH Yang
Publikováno v:
Marine Drugs, Vol 16, Iss 12, p 489 (2018)
A marine sesterterpenoid-type natural product, heteronemin, retains anticancer effects. In the current study, we investigate the antitumor mechanism of heteronemin in cholangiocarcinoma cells and further explore its molecular targets. Initially, hete
Externí odkaz:
https://doaj.org/article/194124cfcd354affbaaedb107f3503f0
Autor:
Ya Jung Shih, Yu Tang Chin, Shwu Jiuan Lin, Heng Yuan Tang, Hung Yun Lin, Yi Ru Chen, Hsuan Liang Liu, Paul J. Davis, Szu Yi Chou, Jacqueline Whang-Peng, Yih Ho, Yu Chen Sh Yang, Chun A. Changou
Publikováno v:
Food and Chemical Toxicology. 120:346-355
Leiomyomas (myomas) are the most common benign smooth muscle cell tumor of the myometrium. Resveratrol, a stilbene, has been used as an anti-inflammatory and antitumor agent. In the current study, we investigated the inhibitory effect of resveratrol
Autor:
Hung Yun Lin, Shwu Huey Wang, Yi Ru Chen, Chih Hsiung Wu, Liang Shun Wang, André Wendindondé Nana, Yu Chen Sh Yang, Ya Jung Shih, Tung Cheng Chang, Jacqueline Whang-Peng, Ai Shih, Yu Tang Chin, Kuan Wang, Chun A. Changou, Yu Min Liao, Steven C. Stain, Paul J. Davis
Publikováno v:
Hormones & Cancer
Drug resistance complicates the clinical use of gefitinib. Tetraiodothyroacetic acid (tetrac) and nano-diamino-tetrac (NDAT) have been shown in vitro and in xenografts to have antiproliferative/angiogenic properties and to potentiate antiproliferativ
Autor:
Chun A. Changou, Yu Tang Chin, Yih Ho, Yu Chen Sh Yang, Meng Ti Hsieh, André Wendindondé Nana, Ya Jung Shih, Po Li Wei, Paul J. Davis, Aleck Hercbergs, Hung Yun Lin, Yi Ru Chen
Publikováno v:
Endocrine-Related Cancer. 25:533-545
Thyroid hormone,l-thyroxine (T4), has been shown to promote ovarian cancer cell proliferation via a receptor on plasma membrane integrin αvβ3 and to induce the activation of ERK1/2 and expression of programmed death-ligand 1 (PD-L1) in cancer cells
Autor:
Yu Chen Sh Yang, Yi-Chang Liu, Jacqueline Whang-Peng, Yung Ning Yang, Hung Yun Lin, Kuan Wang, Yu Cheng Chen, Shu Leei Tey, Ya Jung Shih, Yih Ho, Yung Tang Chin, Yi Ru Chen, Heng Yuan Tang
Publikováno v:
Marine Drugs, Vol 16, Iss 12, p 489 (2018)
Marine Drugs
Volume 16
Issue 12
Marine Drugs
Volume 16
Issue 12
A marine sesterterpenoid-type natural product, heteronemin, retains anticancer effects. In the current study, we investigate the antitumor mechanism of heteronemin in cholangiocarcinoma cells and further explore its molecular targets. Initially, hete
Autor:
Yee Tong Lim, Earl Fu, Paul J. Davis, Szu Yi Chou, Jacqueline Whang-Peng, Kuan Wang, Ya Jung Shih, Yu Chen Sh Yang, Shan Jen Lin, André Wendindondé Nana, Yih Ho, Yi Ru Chen, Yu Tang Chin, Sheng‐Yang Y. Lee, Hung Yun Lin, Kuan Wei Su
Publikováno v:
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 120
Programmed death-ligand 1 (PD-L1) is a critical regulator to defend tumor cells against immune surveillance. Thyroid hormone has been shown to induce PD-L1 expression in cancer cells. Its nano-particulated analogue, nano-diamino-tetrac (NDAT; Nanotet
Autor:
Hung Yun Lin, Jens Z. Pedersen, Ya Jung Shih, Szu Yuan Wu, Yu Tang Chin, Yun Ru Liu, Yu Chen Sh Yang, Yu Min Liao, Aleck Hercbergs, Sandra Incerpi, Paul J. Davis, Wen-Shan Li, Tsai Mu Cheng, André Wendindondé Nana, Leroy F. Liu, Yih Ho, Jacqueline Whang-Peng, Yi Ru Chen
Cancer resistance to chemotherapeutic agents is a major issue in the management of cancer patients. Overexpression of the ribonucleotide reductase regulatory subunit M2 (RRM2) has been associated with aggressive cancer behavior and chemoresistance. N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0c42adfa752f7dd0f5219e7c9fe0d2
http://www.springer.com/medicine/oncology/journal/12672
http://www.springer.com/medicine/oncology/journal/12672